The Conversation (0)
The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Jan. 04, 2017 08:26AM PST
Biotech Investing
The 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field.
SAN FRANCISCO, CA–(Marketwired – January 04, 2017) – Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco on January 11.
Included in this article are:
Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM)
Asterias Biotherapeutics Inc. (NYSE MKT: AST)
The collection of small-cap biotechs on the 2017 Watchlist are developing therapies to address diverse indications including rare diseases, asthma, inflammatory bowel disease, spinal cord injury, hemophilia, and a number of cancers. The platforms are equally diverse, representing traditional biologics, cell therapies and vaccines. Watchlist companies include:
Actinium Pharmaceuticals Inc.: ~$55M market cap. Actinium is in a pivotal Phase 3 trial with its lead candidate, Iomab-B, a radioimmunotherapy used prior to a bone marrow transplant in relapsed and refractory acute myeloid leukemia patients over the age of 55. It also has a second radioimmunotherapy, Actimab-A, in clinical study.
Asterias Biotherapeutics Inc. : ~$226M market cap. This stem cell company is addressing two key markets: spinal cord injury and cancer, with a dendritic cell (DC) therapy using genetically engineered autologous and allogeneic stem cells.
Continue reading this article: 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Please see the end of the article for the complete disclosure: 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Included in this article are:
Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM)
Asterias Biotherapeutics Inc. (NYSE MKT: AST)
The collection of small-cap biotechs on the 2017 Watchlist are developing therapies to address diverse indications including rare diseases, asthma, inflammatory bowel disease, spinal cord injury, hemophilia, and a number of cancers. The platforms are equally diverse, representing traditional biologics, cell therapies and vaccines. Watchlist companies include:
Actinium Pharmaceuticals Inc.: ~$55M market cap. Actinium is in a pivotal Phase 3 trial with its lead candidate, Iomab-B, a radioimmunotherapy used prior to a bone marrow transplant in relapsed and refractory acute myeloid leukemia patients over the age of 55. It also has a second radioimmunotherapy, Actimab-A, in clinical study.
Asterias Biotherapeutics Inc. : ~$226M market cap. This stem cell company is addressing two key markets: spinal cord injury and cancer, with a dendritic cell (DC) therapy using genetically engineered autologous and allogeneic stem cells.
Continue reading this article: 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Please see the end of the article for the complete disclosure: 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Contact Information:
Carrie Beal Amaro
Associate Publisher
Email contact
Carrie Beal Amaro
Associate Publisher
Email contact